Gates Foundation awards $6 million grant to NanoBio for intranasal RSV vaccine

University of Michigan spin-off NanoBio Corporation has received its second grant for vaccine development from the Bill and Melinda Gates Foundation. The new $6 million grant is for development of an intranasal vaccine for respiratory syncytial virus (RSV). No approved RSV vaccines are available currently. In 2005, prior to the spin off from UM, the company received $6.3 million from the Gates Foundation for intranasal vaccine development. Read the company’s press release.

Share

published on

May 10-May 14RDD 2026, Phoenix, AZ, USA

May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA

May 17-May 20: ATS International Conference 2026, Orlando, FL, USA

June 10SMI.London 2026, London, UK

July 13-July 162026 ISAM Congress, Taipei, Taiwan